Cui Y - Search Results

1

Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.

Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Andò S, Fuqua SA. Barone I, et al. Among authors: cui y. Cancer Res. 2009 Jun 1;69(11):4724-32. doi: 10.1158/0008-5472.CAN-08-4194. Cancer Res. 2009. PMID: 19487288 Free PMC article.

2

Accelerated mammary maturation and differentiation, and delayed MMTVneu-induced tumorigenesis of K303R mutant ERalpha transgenic mice.

Herynk MH, Lewis MT, Hopp TA, Medina D, Corona-Rodriguez A, Cui Y, Beyer AR, Fuqua SA. Herynk MH, et al. Among authors: cui y. Oncogene. 2009 Sep 10;28(36):3177-87. doi: 10.1038/onc.2009.174. Epub 2009 Jun 29. Oncogene. 2009. PMID: 19561644 Free PMC article.

3

Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.

Barone I, Iacopetta D, Covington KR, Cui Y, Tsimelzon A, Beyer A, Andò S, Fuqua SA. Barone I, et al. Among authors: cui y. Oncogene. 2010 Apr 22;29(16):2404-14. doi: 10.1038/onc.2009.520. Epub 2010 Jan 25. Oncogene. 2010. PMID: 20101208 Free PMC article.

4

Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.

Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Hopp TA, et al. Among authors: cui y. Clin Cancer Res. 2004 Nov 15;10(22):7490-9. doi: 10.1158/1078-0432.CCR-04-1114. Clin Cancer Res. 2004. PMID: 15569979

5

Estrogen and progesterone receptor isoforms: clinical significance in breast cancer.

Fuqua SA, Cui Y. Fuqua SA, et al. Among authors: cui y. Breast Cancer Res Treat. 2004;87 Suppl 1:S3-10. doi: 10.1007/s10549-004-1577-4. Breast Cancer Res Treat. 2004. PMID: 15597215

6

Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity.

Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA. Cui Y, et al. Cancer Res. 2004 Dec 15;64(24):9199-208. doi: 10.1158/0008-5472.CAN-04-2126. Cancer Res. 2004. PMID: 15604293

7

Targeting the estrogen receptor in clinical breast cancer.

Fuqua SA, Cui Y. Fuqua SA, et al. Among authors: cui y. Breast Dis. 2002;15:3-11. doi: 10.3233/bd-2002-15102. Breast Dis. 2002. PMID: 15687641

8

Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells.

Cui Y, Niu A, Pestell R, Kumar R, Curran EM, Liu Y, Fuqua SA. Cui Y, et al. Mol Endocrinol. 2006 Sep;20(9):2020-35. doi: 10.1210/me.2005-0063. Epub 2006 Apr 27. Mol Endocrinol. 2006. PMID: 16645043 Free PMC article.

9

Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance.

Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, Fuqua SA. Cui Y, et al. Cancer Res. 2006 Jun 1;66(11):5950-9. doi: 10.1158/0008-5472.CAN-05-3243. Cancer Res. 2006. PMID: 16740736 Free PMC article.

10

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.

Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, Fuqua SA. Herynk MH, et al. Among authors: cui y. Mol Cancer Ther. 2006 Dec;5(12):3023-31. doi: 10.1158/1535-7163.MCT-06-0394. Mol Cancer Ther. 2006. PMID: 17172405

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18,587 results

Search Page

Filters